The development of anticyclic citrullinated peptide (anti-CCP) antibody following severe COVID-19.

Seyed Askar RoghaniMohammad DastbazRamin LotfiAfsaneh ShamsiZahra AbdanRezvan RostampourBijan SoleymaniMohammad Hossein ZamanianParviz SoufivandMehran PournazariMahdi Taghadosi

Published in: Immunity, inflammation and disease (2024)

Our study further supports the development of autoantibodies related to systemic autoimmune rheumatologic diseases. To the best of our knowledge, this is the first study with a large sample size that reported the occurrence of anti-CCP in a severe form of COVID-19.

Keyphrases

coronavirus disease
sars cov
healthcare
early onset
drug induced
risk assessment
multiple sclerosis
respiratory syndrome coronavirus